VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

M-M-R II
Vaccine Information
  • Vaccine Name: M-M-R II
  • Target Pathogen: Rubella virus
  • Target Disease: Rubella
  • Product Name: Measles, Mumps, and Rubella Virus Vaccine, Live
  • Tradename: M-M-R II
  • Manufacturer: Merck & Co., Inc.
  • Vaccine Ontology ID: VO_0000069
  • CDC CVX code: 03
  • Type: Live, attenuated vaccine
  • Status: Licensed
  • Location Licensed: USA(License #0002)
  • Host Species for Licensed Use: Human
  • Preparation: The growth medium for rubella is Minimum Essential Medium (MEM) [a buffered salt solution containing vitamins and amino acids and supplemented with fetal bovine serum] containing recombinant human albumin and neomycin. Sorbitol and hydrolyzed gelatin stabilizer are added to the individual virus harvests (FDA: MMR-II).
  • Immunization Route: Intramuscular injection (i.m.)
  • Storage: 2 to 8°C (36 to 46°F) or colder. Do not freeze.
  • Approved Age for Licensed Use: 12 months or older
  • Contraindication: Hypersensitivity to any component of the vaccine, a history of anaphylactic or anaphylactoid reactions to neomycin (FDA: MMR-II).
  • Description: M-M-R II is a sterile lyophilized preparation of (1) ATTENUVAX* (Measles Virus Vaccine Live), a more attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture; (2) MUMPSVAX* (Mumps Virus Vaccine Live), the Jeryl Lynn** (B level) strain of mumps virus propagated in chick embryo cell culture; and (3) MERUVAX* II (Rubella Virus Vaccine Live), the Wistar RA 27/3 strain of live attenuated rubella virus propagated in WI-38 human diploid lung fibroblasts (FDA: MMR-II).
Host Response

Human Response

  • Immune Response: Neutralizing and ELISA antibodies to measles, mumps, and rubella viruses are still detectable in most individuals 11 to 13 years after primary vaccination (FDA: MMR-II).
  • Side Effects: Side effects of vaccination are: fever, headache, dizziness, and irritability.
  • Efficacy: Many clinical studies have shown the vaccine have a high rate of efficacy protection after vaccination with MMR-II (FDA: MMR-II).
References
FDA: MMR-II: FDA: MMR-II Vaccine [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094050.htm]